Archives
Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Technical G
2026-05-07
Phosphatase Inhibitor Cocktail 3 (100X in DMSO) addresses the challenge of preserving protein phosphorylation during sample preparation by inhibiting alkaline and serine/threonine phosphatases, such as PP1 and PP2A. This product is best suited for workflows requiring accurate phosphoprotein analysis, including Western blot and kinase assays, but should not be used in applications where phosphatase activity is required for the experimental objective.
MDV3100 (Enzalutamide): Applied Workflows in Prostate Cancer
2026-05-07
MDV3100 (Enzalutamide) delivers robust inhibition of androgen receptor signaling, empowering prostate cancer researchers to dissect apoptosis, resistance, and glycosaminoglycan-driven phenotypes. This guide distills protocol parameters, advanced applications, and troubleshooting strategies—anchored by the latest evidence on UGDH phosphorylation and therapeutic evasion.
Y-27632: Precision ROCK Inhibitor for Cytoskeletal Modulatio
2026-05-06
Y-27632 is the benchmark ROCK inhibitor for dissecting cytoskeletal dynamics and optimizing advanced cell models. This guide details experimental workflows, application-specific enhancements, and troubleshooting strategies—empowering translational researchers to drive reproducible outcomes in cancer biology and regenerative studies.
CAFs-Derived Lactate Drives Oxaliplatin Resistance via ANTXR
2026-05-06
This study uncovers how lactate secreted by cancer-associated fibroblasts (CAFs) fosters resistance to oxaliplatin in colorectal cancer by promoting cancer stemness through ANTXR1 lactylation. The findings provide mechanistic insights into tumor-stroma interactions and suggest novel avenues for overcoming chemoresistance.
Microbiota–Tryptophan–AhR Axis in Intestinal Repair and UC
2026-05-05
Li et al. (2026) reveal that Huangqin decoction (HQD) repairs ulcerative colitis by reshaping gut microbiota and tryptophan metabolism, thereby activating the aryl hydrocarbon receptor (AhR) and promoting intestinal stem cell (ISC) differentiation. This work uncovers a mechanistic axis linking microbial metabolites and epithelial renewal, with implications for targeted interventions in barrier restoration.
Atorvastatin in Ferroptosis: Advancing Cancer and Vascular R
2026-05-05
Explore how Atorvastatin, a potent HMG-CoA reductase inhibitor, is reshaping cholesterol metabolism research and illuminating new pathways in ferroptosis-driven cancer studies. This article uniquely deciphers recent findings and protocol implications for translational science.
Redefining Cell Cytotoxicity Measurement for Translational R
2026-05-04
This thought-leadership article explores how mechanistic understanding and strategic deployment of LDH cytotoxicity assays—exemplified by the APExBIO LDH Cytotoxicity Assay Kit—are transforming the landscape of translational biomedical research. Drawing on cutting-edge nanomaterial biocompatibility studies, it bridges experimental rationale, workflow guidance, and translational impact, while contrasting best-in-class assay solutions with traditional approaches. The article integrates recent findings on magnetite-coated cellulose nanocrystals and provides actionable recommendations for protocol optimization, all grounded in evidence and workflow maturity.
Z-VDVAD-FMK: Benchmark Irreversible Caspase-2 Inhibitor Prof
2026-05-04
Z-VDVAD-FMK is a cell-permeable, irreversible caspase-2 inhibitor used to dissect apoptotic pathways. This compound, also known as benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone, covalently targets the caspase active site to block proteolytic activity. Its validated specificity and protocol versatility make it a gold standard in apoptosis and mitochondrial signaling research.
Viral Modulation of RIPK3: Mechanisms Controlling Necroptosi
2026-05-03
Liu et al. (2021) identify a class of orthopoxvirus proteins that induce proteasomal degradation of the necroptosis adaptor RIPK3, thereby regulating virus-induced inflammation and host-pathogen interactions. This study elucidates a critical viral immune evasion strategy, with implications for understanding cell death regulation in infectious and inflammatory contexts.
Optimizing Cystic Fibrosis Research with VX-661 F508del CFTR
2026-05-02
APExBIO’s VX-661 (F508del CFTR corrector) empowers researchers to restore mutant CFTR trafficking and function with precision, thanks to data-driven workflows and insights into calnexin-dependent protein rescue. This guide delivers actionable protocols, troubleshooting tips, and a synthesis of the latest research, ensuring advanced reproducibility in cystic fibrosis studies.
Y-27632 (SKU B1293): Practical Guide for ROCK Inhibition
2026-05-01
Y-27632 is a selective ROCK inhibitor used to modulate cytoskeletal dynamics and disrupt actin stress fiber formation in cell biology research. This compound is suitable for studies involving ROCK signaling pathway research, but should not be used for diagnostic or clinical applications. Researchers must ensure proper solubilization and storage to maintain experimental consistency.
10058-F4: Unraveling c-Myc-Max Inhibition in Stem Cell Telom
2026-05-01
Explore how 10058-F4, a potent c-Myc-Max dimerization inhibitor, advances stem cell research by directly modulating telomerase expression. This article delivers unique insights into TERT regulation and practical protocols, setting it apart from standard oncology-focused content.
(S)-(+)-Ibuprofen: COX Inhibitor Workflows & Troubleshooting
2026-04-30
(S)-(+)-Ibuprofen from APExBIO delivers high-purity, selective COX inhibition ideal for inflammation pathway research and pain mechanism studies. This guide dives into protocol optimization, real-world troubleshooting, and advanced applications to maximize reproducibility and scientific rigor.
Neticonazole Hydrochloride: Dual-Use Imidazole Antifungal Wo
2026-04-30
Neticonazole Hydrochloride bridges advanced antifungal and oncology research, uniquely inhibiting fungal cell membranes and exosome-mediated cancer progression. This guide delivers stepwise protocols, troubleshooting, and cross-domain insights to maximize scientific impact in both infectious disease and colorectal cancer studies.
FBXO22 Degraders and 2-PCA: New Tools for Targeted Protein D
2026-04-29
This study introduces potent chemical probes—including a selective degrader and a novel 2-pyridinecarboxaldehyde (2-PCA) ligand—for manipulating the E3 ubiquitin ligase FBXO22 in targeted protein degradation (TPD) strategies. These advances expand the repertoire of TPD tools beyond commonly used ligases, with important implications for cancer biology and chemical biology research.
614 records 23/41 page Previous Next First page 上5页 2122232425 下5页 Last page